Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of ixabepilone and
mitoxantrone hydrochloride when given together with prednisone and to see how well they work
in treating patients with metastatic prostate cancer that did not respond to hormone therapy
and chemotherapy. Drugs used in chemotherapy, such as ixabepilone, mitoxantrone
hydrochloride, and prednisone, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving more than one drug
(combination chemotherapy) may kill more tumor cells
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Epothilone B Epothilones Hormones Mitoxantrone Prednisone